The Cell Therapy Manufacturing Market Is Estimated To Witness High Growth Owing To Advancement In Biologics And Biosimilar Therapeutics
The cell therapy manufacturing market is estimated to be valued at US$ 12.99 Mn in 2023 and is expected to exhibit a CAGR of 15% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Cell therapy involves using human cells to treat diseases. It holds potential in treatment of various diseases like cancer, neurological disorders, and cardiovascular illnesses. The market is growing due to advancement in regenerative medicines using stem cells, CAR T-cell therapy, and gene therapy vectors.
Market Dynamics:
The growth of the market is attributed to two key drivers - first, increasing demand for cell therapies due to rising prevalence of chronic diseases and need for effective therapeutics. Cell therapies have shown promise in treatments of cancer, diabetes, and neurological conditions. Second, advancement in bioprocessing technologies enable efficient manufacturing of cell therapies at lower costs. Continuous bioreactors, cell cloning techniques, and process automation have improved manufacturing efficiency and yield. However, high initial costs and regulatory risks are some challenges for the market. Stringent regulations for product approval also increase clinical trial timelines and costs.
SWOT Analysis
Strength:
- Cell therapy manufacturing market size is growing rapidly due to increasing adoption of regenerative medicines and growing cancer research.
- Advancements in cell culturing technologies and automated manufacturing processes help improve production efficiency and quality.
- Increasing investments from key players to develop innovative cell therapies.
Weakness:
- High costs associated with cell therapy development and manufacturing makes it inaccessible for many patients.
- Stringent regulatory processes increase development timelines and costs of new cell therapies.
Opportunity:
- Growing elderly population and incidence of chronic diseases drive the demand for cell therapy products.
- Collaboration between academic research institutes and industry helps expedite clinical translation of cell therapies.
Threats:
- Limited donation of adult stem cells restrains the supply of raw materials.
- Manufacturing complexities associated with maintaining cell viability and functionality.
Key Takeaways
The global cell therapy manufacturing market is expected to witness high growth, exhibiting CAGR of 15% over the forecast period, due to increasing research on stem cell therapy and personalized medicines. The market size is projected to reach US$ 12.99 Bn by 2023 from US$ 99.2 Mn in 2020.
Regional analysis:
North America dominates the global market due to presence of leading market players and growing funding for cell-based research in the US. Asia Pacific exhibits the fastest growth due to rising healthcare spending, developing research infrastructure and increasing patient population.
Key players:
Key players operating in the cell therapy manufacturing market are WuXi AppTec, Inc., Lineage Cell Therapeutics, Inc., HEALIOS K.K., Lonza, Merck KGaA., Takara Bio Inc., Sumitomo Dainippon Pharma Co., LTD, Fujifilm Holdings Corporation, Thermo Fisher Scientific, Inc., Astellas Pharma Inc. These players are focusing on new product launches, expansions and partnerships to strengthen their market position.
Get more insights on this topic: https://www.newswirestats.com/cell-therapy-manufacturing-market-size-and-outlook/
Explore more information, Please visit: https://www.newsintv.com/news/offshore-the-decommissioning-a-best-growing-sector/
English
Arabic
Français
Español
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian